查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401165

全球抗菌药物抗药性监测市场：市场规模、占有率、趋势分析、机会、预测（2019-2029）

Antimicrobial Resistance Surveillance Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Solution ; By Application ; By End User ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计2029年全球抗菌药物抗药性监测市场规模将达79.2亿美元，2023年至2029年复合年增长率为5.6%，稳定成长。

由于越来越多地采用创新诊断技术来诊断和治疗日益增加的医院感染，全球抗菌药物抗药性监测市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的一项研究中估计，2022 年全球抗菌药物抗药性监测市场规模将达到 57.1 亿美元。 BlueWeave 预测，在 2023-2029 年预测期内，全球抗菌素抗药性监测市场规模将以 5.6% 的复合年增长率成长，到 2029 年将达到 79.2 亿美元。全球抗菌素抗药性监测市场的主要成长动力是：由抗药性病原体引起的感染疾病发病率不断增加、诊断技术的进步、对抗菌素抗药性的日益关注以及解决抗菌素抗药性的需求不断增加。政府的配合措施和出现与药物滥用相关的多重抗药性。值得注意的是，先进的成像技术现在可以快速提供临床资讯，而传统的基于培养的方法可能需要长达 48 小时才能产生敏感性资料。无需冗长培养步骤即可检测抗药性的新技术的出现将诊断时间缩短了至少一天。更快、更先进的诊断测试预计将推动抗菌素抗药性诊断市场的成长。此外，住院期间发生的院内感染包括多种疾病。医院感染，如中心静脉管相关的血流感染疾病和导管相关的泌尿道尿道感染感染疾病普遍。这些感染疾病的流行势必会推动抗菌素抗药性诊断市场的发展，反映出现代医疗保健中侵入性技术和设备的使用越来越多。然而，最终用户与抗菌素抗药性监测系统和套件相关的高成本和技术挑战预计将限制预测期内的整体市场成长。

机会 -配合措施提高对抗菌素抗药性及其控制的认识

抗菌素抗药性 (AMR) 是对人类健康的一种广泛的全球威胁，促使人们在 2015 年透过《抗菌素抗药性全球行动计画》(GAP-AMR) 采取统一应对措施。该倡议旨在透过负责任地提供有效、安全和有品质保证的药物来确保感染疾病治疗的持续成功。主导全球抗生素抗药性和使用监测系统 (GLASS) 领导的监测对于政策制定和感染控制至关重要。 GLASS 标准化了资料收集、分析和解释，促进涵盖流行病学、临床和人口层面资料的全面监测过渡。 GLASS 积极配合措施能力建设，并与世卫组织和区域网络合作，以填补知识空白、为策略资讯资讯并为全球抗微生物药物抗药性认识工作做出重大贡献。

COVID-19 对全球抗菌药物抗药性监测市场的影响

COVID-19 大流行对全球抗菌药物抗药性监测市场产生了积极影响。有几个因素导致了这种情况的恶化，包括对COVID-19 患者使用抗生素的增加、不堪重负的医疗系统内感染控制措施的中断以及将资源从监测和应对抗菌素抗药性(AMR) 的威胁转移到其他地方。大流行需要引入虚拟咨询和快速诊断测试，以最大程度地减少医院就诊次数。在疫情大流行后，家庭医疗保健仍然至关重要，特别是对于患有既往疾病的患者来说，并且预计将刺激对诊断测试的需求。

全球抗菌药物抗药性监测市场—按最终用户

按最终用户划分，全球抗菌素抗药性监测市场分为医院和诊所部分以及研究和学术机构部分。医院和诊所部门在最终用户的抗菌药物抗药性监测全球市场中占有很高的占有率，这主要是由于医院和诊所观察到的患者密度不断增加。由于医院感染发生率不断增加，维持严格的感染控制方案是必要的基本的。

全球抗菌素抗药性监测市场—按地区

本研究报告调查分析了全球抗菌药物抗药性监测市场，并列出了五个主要地区的各国市场。这些地区是北美、欧洲、亚太地区、拉丁美洲和中东/非洲。北美在全球抗菌药物抗药性监测市场中占最高占有率。该地区的优势在于其在美国和加拿大拥有完善的医疗保健系统和先进的检测设施。这些主要国家正在大力投资抗菌素抗药性 (AMR) 监测，重点是临床诊断和资料收集。该地区强大的医疗基础设施和高标准的患者照护支持北美临床诊断的很大占有率。值得注意的是，美国疾病管制与预防中心 (CDC) 正在带头进行抗菌素抗药性监测工作。同时，亚太地区预计在预测期内将呈现最快的成长率。特别是中国，在抗菌素抗药性监测方面进行了大量投资，并建立了全国性的资料收集网路。与世界卫生组织（WHO）等国际组织的合作进一步加强了该地区的配合措施。亚太地区拥有不同的医疗保健系统和人口规模，包括中国和印度，并面临着独特的挑战，导致区域和全球卫生组织推动的公共卫生监测工作配合措施。我是。

竞争形势

全球抗菌药物抗药性监测市场的主要企业包括 Becton Dickinson、bioMérieux、Thermo Fisher Scientific、Danaher、Luminex、Bruker、Bio-Rad、Qiagen 和 Abbott Laboratories、Roche Diagnostics、Opgen、Wolters Kluwer、Lumed、Biospace 和造父变星。为了进一步增加市场占有率，这些公司正在采取各种策略，例如併购、合作、合资、授权协议和新产品发布。

该报告的详细分析提供了有关全球抗菌素抗药性监测市场的成长潜力、未来趋势和统计数据的资讯。它还涵盖了推动市场总规模预测的因素。该报告致力于提供全球抗菌素抗药性监测市场的最新技术趋势以及产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长动力、挑战和竞争力。

目录

第一章 研究框架

第 2 章执行摘要

第 3 章：全球抗菌药物抗药性监测市场洞察

  • 产业价值链分析
  • DROC分析
    • 生长促进因子
      • 诊断技术不断创新
      • 医院感染增加
    • 抑制因素
      • 与抗菌药物抗药性监测系统和套件相关的高成本
      • 最终用户技术挑战
    • 机会
      • 意识提升的配合措施
      • 新兴经济体的成长机会
    • 任务
      • 复杂的法律规范
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第四章全球抗菌药物抗药性监测市场概述

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
      • 诊断套件
      • 诊断系统
      • 监控软体
      • 服务
    • 按用途
      • 临床诊断
      • 公共卫生监测
      • 其他的
    • 按最终用户
      • 医院/诊所
      • 研究/学术机构
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第五章北美抗菌药物抗药性监测市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 美国
      • 加拿大

第六章欧洲抗菌药物抗药性监测市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 欧洲其他地区

第七章亚太地区抗菌药物抗药性监测市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲/纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 其他亚太地区

第八章拉丁美洲抗菌药物抗药性监测市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 其他拉丁美洲

第九章中东和非洲抗菌药物抗药性监测市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按解决方案
    • 按用途
    • 按最终用户
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • 其他中东/非洲

第10章竞争形势

  • 主要企业及产品列表
  • 2022 年全球抗菌药物抗药性监测市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）

第十一章 COVID-19 对全球抗生素抗药性监测市场的影响

第十二章 公司简介

  • Becton, Dickinson and Company
  • Biomerieux
  • Thermo Fisher Scientific
  • Danaher
  • Luminex Corporation
  • Bruker
  • Bio-Rad
  • Qiagen
  • Abbott Laboratories
  • Roche Diagnostics
  • OpGen, Inc.
  • Wolters Kluwer NV
  • Lumed
  • BioSpace
  • Cepheid
  • 其他主要企业

第十三章 关键策略建议

第14章调查方法

简介目录
Product Code: BWC231035

Global Antimicrobial Resistance Surveillance Market Size Expands at Steady CAGR of 5.6% During 2023-2029 to Touch USD 7.92 Billion by 2029

Global Antimicrobial Resistance Surveillance Market is flourishing because of increasing adoption of innovative diagnostic technologies to diagnose and treat growing incidences of hospital-acquired infections.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antimicrobial Resistance Surveillance Market size at USD 5.71 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects Global Antimicrobial Resistance Surveillance Market size to grow at a CAGR of 5.6% reaching a value of USD 7.92 billion by 2029. Major growth drivers for the Global Antimicrobial Resistance Surveillance Market include an increasing incidence of infections attributed to drug-resistant pathogens, advancements in diagnostic technologies, a rising concern over antimicrobial resistance, governmental efforts to address antimicrobial resistance, and the emergence of multi-drug resistance linked to drug abuse. Notably, advanced imaging technologies now deliver clinical information swiftly, contrasting with traditional culture-based methods taking up to 48 hours for susceptibility data. The emergence of new techniques detecting drug resistance without lengthy culture processes shortens the diagnostic timeframe by at least a day. Faster and more advanced diagnostic tests are expected to drive growth in the antimicrobial resistance diagnostics market. Also, nosocomial infections, acquired during hospitalization, encompass diverse illnesses. Hospital-acquired infections, such as central line-associated bloodstream infections and urinary tract infections from catheters, are widespread. The prevalence of these infections is poised to boost the antimicrobial resistance diagnostics market, reflecting the growing use of invasive techniques and equipment in modern healthcare. However, high costs associated with antimicrobial resistance surveillance system and kits and technical challenges in the end-user are anticipated to restrain the overall market growth during the forecast period.

Opportunity - Initiatives to Increase Awareness about Antimicrobial Resistance and Control

Antimicrobial resistance (AMR) is a pervasive global threat to human health, prompting a unified response through the Global Action Plan for AMR (GAP-AMR) in 2015. The initiative aims to ensure sustained success in treating infectious diseases by providing effective, safe, and quality-assured medicines responsibly. Surveillance, led by the Global Antimicrobial Resistance and Use Surveillance System (GLASS), is pivotal for policy formulation and infection control. GLASS standardizes data collection, analysis, and interpretation, promoting a shift towards comprehensive surveillance encompassing epidemiological, clinical, and population-level data. It actively engages in capacity building and partners with WHO and regional networks to bridge knowledge gaps and inform strategies, contributing significantly to global AMR awareness initiatives.

Impact of COVID-19 on Global Antimicrobial Resistance Surveillance Market

COVID-19 pandemic had a positive impact on Global Antimicrobial Resistance Surveillance Market. Several factors contributed to this exacerbation, including heightened antibiotic use for COVID-19 patients, disruptions in infection control measures within overwhelmed healthcare systems, and the redirection of resources away from monitoring and addressing antimicrobial resistance (AMR) threats. The pandemic necessitated the adoption of virtual visits and rapid diagnostic testing to minimize hospital visits. Even post-pandemic, home-based healthcare is expected to remain essential, particularly for individuals with pre-existing conditions, thereby fueling the demand for diagnostic assays.

Global Antimicrobial Resistance Surveillance Market - By End User

On the basis of end user, the Global Antimicrobial Resistance Surveillance Market is split into Hospitals & Clinics and Research & Academic Institutes segments. The hospitals & clinics segment holds a higher share in the Global Antimicrobial Resistance Surveillance Market by end user, primarily due to the elevated patient density observed in hospitals and clinics, the rising incidence of nosocomial infections within hospital settings, and the imperative to uphold stringent infection control protocols.

Global Antimicrobial Resistance Surveillance Market - By Region

The in-depth research report on the Global Antimicrobial Resistance Surveillance Market covers various country-specific markets across five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America region holds the highest share in the Global Antimicrobial Resistance Surveillance Market. The region's dominance is attributed to its well-established healthcare systems and advanced laboratory facilities in the United States and Canada. These major countries exhibit substantial investments in antimicrobial resistance (AMR) surveillance, with a specific focus on clinical diagnostics and data collection. The region's robust healthcare infrastructure and high standards of patient care contribute to the significant share held by clinical diagnostics in North America. Notably, the Centers for Disease Control and Prevention (CDC) in the United States spearhead AMR surveillance efforts. Meanwhile, the Asia Pacific region is expected to witness the fastest growth rate during the forecast period. China, in particular, has made noteworthy investments in AMR surveillance, establishing a national data collection network. Collaboration with international organizations, such as the World Health Organization (WHO), further enhances the region's efforts. The Asia Pacific region, encompassing diverse healthcare systems and population sizes, including China and India, encounters distinct challenges, prompting an upsurge in public health surveillance initiatives facilitated by regional and global health organizations.

Competitive Landscape

Major players operating in the Global Antimicrobial Resistance Surveillance Market include Becton, Dickinson and Company, Biomerieux, Thermo Fisher Scientific, Danaher, Luminex Corporation, Bruker, Bio-Rad, Qiagen, Abbott Laboratories, Roche Diagnostics, OpGen, Inc., Wolters Kluwer N.V., Lumed, BioSpace, and Cepheid. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antimicrobial Resistance Surveillance Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antimicrobial Resistance Surveillance Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Antimicrobial Resistance Surveillance Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing innovation in diagnostic technologies
      • 3.2.1.2. Increasing incidences of hospital-acquired infections
    • 3.2.2. Restraints
      • 3.2.2.1. High costs associated with antimicrobial resistance surveillance system and kits
      • 3.2.2.2. Technical challenges in the End User
    • 3.2.3. Opportunities
      • 3.2.3.1. Awareness initiatives for antimicrobial resistance and control
      • 3.2.3.2. Growth opportunities in emerging economies
    • 3.2.4. Challenges
      • 3.2.4.1. Complex regulatory framework
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Antimicrobial Resistance Surveillance Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Solution
      • 4.2.1.1. Diagnostic kits
      • 4.2.1.2. Diagnostic systems
      • 4.2.1.3. Surveillance software
      • 4.2.1.4. Services
    • 4.2.2. By Application
      • 4.2.2.1. Clinical Diagnostics
      • 4.2.2.2. Public Health Surveillance
      • 4.2.2.3. Other
    • 4.2.3. By End User
      • 4.2.3.1. Hospitals & Clinics
      • 4.2.3.2. Research & Academic Institutes
      • 4.2.3.3. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Antimicrobial Resistance Surveillance Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Solution
    • 5.2.2. By Application
    • 5.2.3. By End User
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Solution
      • 5.2.4.1.2. By Application
      • 5.2.4.1.3. By End User
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Solution
      • 5.2.4.2.2. By Application
      • 5.2.4.2.3. By End User

6. Europe Antimicrobial Resistance Surveillance Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Solution
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Solution
      • 6.2.4.1.2. By Application
      • 6.2.4.1.3. By End User
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Solution
      • 6.2.4.2.2. By Application
      • 6.2.4.2.3. By End User
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Solution
      • 6.2.4.3.2. By Application
      • 6.2.4.3.3. By End User
      • 6.2.4.4. France
      • 6.2.4.4.1. By Solution
      • 6.2.4.4.2. By Application
      • 6.2.4.4.3. By End User
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Solution
      • 6.2.4.5.2. By Application
      • 6.2.4.5.3. By End User
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Solution
      • 6.2.4.6.2. By Application
      • 6.2.4.6.3. By End User
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Solution
      • 6.2.4.7.2. By Application
      • 6.2.4.7.3. By End User
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Solution
      • 6.2.4.8.2. By Application
      • 6.2.4.8.3. By End User
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Solution
      • 6.2.4.9.2. By Application
      • 6.2.4.9.3. By End User

7. Asia Pacific Antimicrobial Resistance Surveillance Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Solution
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Solution
      • 7.2.4.1.2. By Application
      • 7.2.4.1.3. By End User
      • 7.2.4.2. India
      • 7.2.4.2.1. By Solution
      • 7.2.4.2.2. By Application
      • 7.2.4.2.3. By End User
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Solution
      • 7.2.4.3.2. By Application
      • 7.2.4.3.3. By End User
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Solution
      • 7.2.4.4.2. By Application
      • 7.2.4.4.3. By End User
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Solution
      • 7.2.4.5.2. By Application
      • 7.2.4.5.3. By End User
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Solution
      • 7.2.4.6.2. By Application
      • 7.2.4.6.3. By End User
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Solution
      • 7.2.4.7.2. By Application
      • 7.2.4.7.3. By End User
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Solution
      • 7.2.4.8.2. By Application
      • 7.2.4.8.3. By End User
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Solution
      • 7.2.4.9.2. By Application
      • 7.2.4.9.3. By End User
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Solution
      • 7.2.4.10.2. By Application
      • 7.2.4.10.3. By End User

8. Latin America Antimicrobial Resistance Surveillance Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Solution
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Solution
      • 8.2.4.1.2. By Application
      • 8.2.4.1.3. By End User
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Solution
      • 8.2.4.2.2. By Application
      • 8.2.4.2.3. By End User
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Solution
      • 8.2.4.3.2. By Application
      • 8.2.4.3.3. By End User
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Solution
      • 8.2.4.4.2. By Application
      • 8.2.4.4.3. By End User
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Solution
      • 8.2.4.5.2. By Application
      • 8.2.4.5.3. By End User

9. Middle East & Africa Antimicrobial Resistance Surveillance Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Solution
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Solution
      • 9.2.4.1.2. By Application
      • 9.2.4.1.3. By End User
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Solution
      • 9.2.4.2.2. By Application
      • 9.2.4.2.3. By End User
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Solution
      • 9.2.4.3.2. By Application
      • 9.2.4.3.3. By End User
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Solution
      • 9.2.4.4.2. By Application
      • 9.2.4.4.3. By End User
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Solution
      • 9.2.4.5.2. By Application
      • 9.2.4.5.3. By End User
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Solution
      • 9.2.4.6.2. By Application
      • 9.2.4.6.3. By End User
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Solution
      • 9.2.4.7.2. By Application
      • 9.2.4.7.3. By End User
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Solution
      • 9.2.4.8.2. By Application
      • 9.2.4.8.3. By End User

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Antimicrobial Resistance Surveillance Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Antimicrobial Resistance Surveillance Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Becton, Dickinson and Company
  • 12.2. Biomerieux
  • 12.3. Thermo Fisher Scientific
  • 12.4. Danaher
  • 12.5. Luminex Corporation
  • 12.6. Bruker
  • 12.7. Bio-Rad
  • 12.8. Qiagen
  • 12.9. Abbott Laboratories
  • 12.10. Roche Diagnostics
  • 12.11. OpGen, Inc.
  • 12.12. Wolters Kluwer N.V.
  • 12.13. Lumed
  • 12.14. BioSpace
  • 12.15. Cepheid
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations